Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKairi Kojo

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies TP53 and RUNX1 mutations as significant predictors of outcomes in adult AML following allo-HSCT, suggesting a need for refined prognostic models.

Key Points

  • Poor outcomes are linked to mutations in TP53 and RUNX1 in adult AML patients after allo-HSCT.
  • The study included 198 adult AML patients with a median age of 52 years, showing differences in survival based on mutation status.
  • Analysis used a retrospective cohort and multivariate methods to assess survival rates and risk factors for patients undergoing transplant.
  • Findings highlight the importance of genetic abnormalities in refining prognostic models for transplant eligibility assessment.

Cite This Study

Kairi Kojo (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d46chttps://doi.org/10.1182/blood-2025-2522
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population2025
  2. 2Risk stratification of newly diagnosed AML receiving nonintensive treatment2025
  3. 3Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  4. 4Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study2025
  5. 5Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide2025